Subject(s)
Bacteremia/microbiology , Campylobacter Infections/complications , Campylobacter jejuni , Adult , Aged , Humans , MaleABSTRACT
The activity of six quinolones (ciprofloxacin, levofloxacin, trovafloxacin, moxifloxacin, clinafloxacin and grepafloxacin) against 86 clinical isolates of Corynebacterium spp. obtained from different clinical sources was studied. Of these, 30 isolates were identified as C. jeikeium, 30 as C. urealyticum and 26 as C. amycolatum. C. amycolatum was the most resistant species, with 85.5% of the strains analyzed resistant to all the quinolones studied. Clinafloxacin showed the best activity against these species with a concentration range between <0.01 and 8 mg/l, and MIC50 and MIC90 64 and 32 times lower, respectively, than the MICs of ciprofloxacin. The majority of the isolates (90%) of C. jeikeium and C. urealyticum were susceptible to all the quinolones studied. Only 9.9% of the C. jeikeium strains and 13.2% of the C. urealyticum strains were resistant to ciprofloxacin, which showed the lowest activity of the antimicrobial agents evaluated. Clinafloxacin, grepafloxacin and moxifloxacin were the most active quinolones against these two multiresistant species.
Subject(s)
Anti-Infective Agents/pharmacology , Corynebacterium/drug effects , Anti-Infective Agents/therapeutic use , Corynebacterium Infections/microbiology , Drug Resistance, Microbial , Fluoroquinolones , Humans , Microbial Sensitivity TestsABSTRACT
Se ha estudiado la actividad de seis quinolonas (ciprofloxacino, levofloxacino, trovafloxacino, moxifloxacino, clinafloxacino y grepafloxacino) frente a 86 aislamientos clínicos de Corynebacterium spp. procedentes de diferentes muestras clínicas. De éstos, 30 pertenecían a la especie C. jeikeium, 30 a C. urealyticum y 26 a C. amycolatum. La especie más resistente fue C. amycolatum, de la cual el 85,5 por ciento de las cepas estudiadas fueron resistentes a todas las quinolonas probadas, siendo clinafloxacino la que presentó una mejor actividad, con un rango de concentración entre <0,01 y 8 mg/l y CMI50 y CMI90 64 y 32 veces inferiores a las de ciprofloxacino, respectivamente. Más del 90 por ciento de las cepas de C. jeikeium y C. urealyticum fueron sensibles a todas las quinolonas, siendo ciprofloxacino la de peor actividad, con un porcentaje de cepas resistentes del 9,9 por ciento en el caso de C. jeikeium y un 13,2 por ciento para C. urealyticum. Clinafloxacino, grepafloxacino y moxifloxacino fueron las nuevas quinolonas más activas frente a estas dos especies de corinebacterias multirresistentes (AU)
